Mersana Therapeutics, Inc.
NASDAQ:MRSN
2.12 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 36.855 | 26.581 | 0.043 | 0.828 | 42.123 | 10.594 | 17.545 | 25.171 | 10.359 |
| Cost of Revenue
| 1.517 | 0.927 | 132.013 | 67.036 | 55.04 | 59.915 | 0.928 | 32.008 | 21.353 |
| Gross Profit
| 35.338 | 25.654 | -131.97 | -66.208 | -12.917 | -49.321 | 16.617 | -6.837 | -10.994 |
| Gross Profit Ratio
| 0.959 | 0.965 | -3,069.07 | -79.961 | -0.307 | -4.656 | 0.947 | -0.272 | -1.061 |
| Reseach & Development Expenses
| 148.269 | 173.385 | 132.013 | 67.036 | 55.04 | 59.915 | 46.7 | 32.008 | 21.353 |
| General & Administrative Expenses
| 59.543 | 56.963 | 36.888 | 21.902 | 17.283 | 16.334 | 10.462 | 6.984 | 5.347 |
| Selling & Marketing Expenses
| -1.517 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 58.026 | 56.963 | 36.888 | 21.902 | 17.283 | 16.334 | 10.462 | 6.984 | 5.347 |
| Other Expenses
| 8.713 | -0.445 | -1.202 | 0 | 0 | 1.398 | 0 | 0 | -0.089 |
| Operating Expenses
| 206.295 | 230.348 | 168.901 | 88.938 | 72.323 | 76.249 | 57.162 | 38.992 | 26.7 |
| Operating Income
| -170.957 | -204.694 | -169.713 | -87.686 | -29.219 | -65.655 | -39.617 | -13.821 | -16.341 |
| Operating Income Ratio
| -4.639 | -7.701 | -3,946.814 | -105.901 | -0.694 | -6.197 | -2.258 | -0.549 | -1.577 |
| Total Other Income Expenses Net
| -0.713 | 0.482 | -0.347 | -0.359 | 1.011 | 1.398 | 0.91 | 0.121 | -0.089 |
| Income Before Tax
| -171.67 | -204.212 | -170.06 | -88.045 | -28.208 | -64.257 | -38.707 | -13.7 | -16.428 |
| Income Before Tax Ratio
| -4.658 | -7.683 | -3,954.884 | -106.335 | -0.67 | -6.065 | -2.206 | -0.544 | -1.586 |
| Income Tax Expense
| 1.349 | 3.328 | -0.855 | 0.359 | -1.011 | 1.398 | 0 | 0 | -0.002 |
| Net Income
| -171.67 | -207.54 | -169.205 | -88.404 | -27.197 | -64.257 | -38.707 | -13.7 | -16.428 |
| Net Income Ratio
| -4.658 | -7.808 | -3,935 | -106.768 | -0.646 | -6.065 | -2.206 | -0.544 | -1.586 |
| EPS
| -1.48 | -2.22 | -2.4 | -1.44 | -0.63 | -2.79 | -3.22 | -0.78 | -0.94 |
| EPS Diluted
| -1.48 | -2.22 | -2.4 | -1.44 | -0.63 | -2.79 | -3.22 | -0.78 | -0.94 |
| EBITDA
| -169.44 | -203.767 | -168.858 | -86.676 | -27.974 | -65.655 | -38.689 | -13.166 | -16.044 |
| EBITDA Ratio
| -4.597 | -7.666 | -3,926.93 | -104.681 | -0.664 | -6.197 | -2.205 | -0.523 | -1.549 |